Evidence summary for the management of insulin injection-related sharps waste disposal in patients with diabetes mellitus / 中国实用护理杂志

Objective:To retrieve and summarize the best evidence related to the management of insulin injection-related sharps waste disposal in diabetic patients at home and abroad, so as to provide reference for clinical healthcare professionals.Methods:This was a evidence-based research. Evidence on insulin injection-related sharps waste management in patients with diabetes, including guidelines, expert consensus, evidence summaries, best practice information sheet, recommended practices, clinical decisions and systematic reviews was systematically searched from domestic and international databases and professional websites, and the search time frame was from the establishment of the database to December 2021. Evidence was extracted and summarized following a quality evaluation of the literature that met the criteria.Results:A total of 15 papers were included, summarizing 25 pieces of best evidence on four areas including risk assessment and management of sharps waste associated with insulin injections, education and training, and the use of safe devices and sharps containers.Conclusions:Best evidence on the management of insulin injection-related sharps waste disposal provides evidence to support clinical practice for healthcare professionals to standardized sharps waste disposal practices in patients with diabetes.

Inmunoterapia con ácaros Valergen por vía sublingual y subcutánea en pacientes alérgicos. Cabaiguán 2010-2019 / Sublingual and subcutaneous Valergen mite immunotherapy in allergic patients in Cabaiguán 2010-2019

RESUMEN Fundamento: La inmunoterapia consiste en la administración de dosis crecientes del alérgeno para controlar la sensibilidad hacia este. Objetivo: Describir el comportamiento de la inmunoterapia por vía subcutánea o sublingual a ácaros. Metodología: Estudio retrospectivo realizado en Cabaiguán, periodo de 2010 a 2019, el universo de 267 pacientes con pruebas positivas a ácaros y la muestra de 53 pacientes. Los datos se obtuvieron del registro de datos. Resultados: Usó la vía sublingual el 60.4 %, predominó el grupo de edad entre 5-18 años (41.5 %), la vía subcutánea se utilizó en un 39.6 %, fue más frecuente en el sexo masculino (58.5 %). La vía subcutánea se indicó mayoritariamente en la rinitis alérgica (20.7 %) y la sublingual en el asma (32.1 %); para ambas, fue el Dermatofagoide pteronyssinus el ácaro de mayor sensibilidad y utilización (43.4 %), el tiempo de administración dominante fue de 3 años (67.9 %). El control de los síntomas se alcanzó con la vía sublingual (37.7 %). En la vía sublingual no se presentaron eventos adversos en el 43.3 %, con la vía subcutánea 11.3 % de los eventos adversos fueron locales y 7.6 % sistémicos leves. Conclusiones: La vía sublingual fue la más utilizada, la de mayor control de los síntomas y menos eventos adversos en el estudio.

ABSTRACT Background: Immunotherapy consists of the administration of the allergen increasing doses to control sensitivity towards it. Objective: To describe the behavior of subcutaneous or sublingual immunotherapy to mites. Methodology: Retrospective study carried out in Cabaiguán, from 2010 to 2019, the universe of 267 patients with positive tests to mites and the sample 53 patients. Data were obtained from the data record. Results: 60.4 % used sublingual, the age group between 5-18 years prevailed (41.5 %), the subcutaneous was used in 39.6 %, and it was more frequent in males (58.5 %). The subcutaneous was indicated mainly in allergic rhinitis (20.7 %) and sublingual in asthma (32.1 %); for both, Dermatofagoide pteronyssinus was the highest sensitivity and use mite (43.4 %) the dominant administration time was 3 years (67.9 %). Symptom control was achieved by sublingual (37.7 %). In sublingual, there were no adverse events in 43.3 %, with the subcutaneous, 11.3 % of the adverse events were local and 7.6 % were mild systemic. Conclusions: Sublingual was the most used, the one with the highest control of symptoms and the fewest adverse events in the study.

Tratamento das cicatrizes atróficas com insulina subcutânea / Atrophic scars treatment with subcutaneous insulin

As cicatrizes atróficas de acne, sequelas persistentes, são indesejáveis e causam impacto negativo cosmético e psicossocial nos pacientes. A questão torna-se mais delicada quando tais cicatrizes localizam-se na região pré-esternal, pelo risco do surgimento de cicatrizes hipertróficas com a realização de procedimentos na região. O papel da insulina na promoção da síntese de proteínas e gorduras é, há muito tempo, reconhecido. A utilização de suas propriedades como fator de crescimento para tratar estas sequelas parece lógica e provou ser gratificante cosmeticamente, com melhora na qualidade de vida

Atrophic acne scars are persistent and undesirable sequelae that have a negative cosmetic and psychosocial impact on patients. This issue becomes more delicate when such scars are located in the presternal region due to the risk of hypertrophic scars appearing when performing these procedures in the area. The literature has long recognized the role of insulin in promoting protein and fat synthesis. Insulin properties as a growth factor to treat these sequelae seems logical and has proved cosmetically satisfying, with quality of life improvement

Práticas de medicações injetáveis: conduta referida de profissionais de enfermagem / Prácticas de medicaciones inyectables: conducta referida de los profesionales de enfermería / Injectable medications: self-reported practices of nursing professionals

RESUMO Objetivo: Identificar a conduta referida de profissionais da enfermagem, do estado de São Paulo, sobre Práticas de Medicações Injetáveis. Método: Estudo tipo survey que identificou a frequência referida sobre Práticas de Medicações Injetáveis mediante resposta de questionário eletrônico, validado, entre setembro e dezembro de 2017. Resultados: Considerando as 1.295 respostas computadas, foram identificadas inconformidades como compartilhamento de frascos multidoses para dois ou mais pacientes (10,8%), reutilização de insumos de uso único, como seringas para salinização de pacientes diferentes (1,2%) e reencape de agulhas após uso (4,9%). Foram referidas maior adesão ao uso de luvas para administração de injeções endovenosas (80,5%) e falta de treinamento para manipulação de dispositivos de segurança (13%). Dados correlacionais apontaram que, quanto maior a idade, melhor era a conduta referida na prática de injetáveis. Conclusão: Embora a maioria das condutas configure-se dentro das Boas Práticas de Medicações Injetáveis, há relatos de práticas de risco, como compartilhamento de insumos de uso único. O treinamento para uso de dispositivos de segurança ainda não é uma realidade para todos os profissionais, visto que muitos o referiram como raro.

RESUMEN Objetivo: Identificar la conducta de profesionales de enfermería del estado de São Paulo sobre Prácticas de Medicaciones Inyectables. Método: Se trata de un estudio tipo survey, el cual identificó la frecuencia de Prácticas de Medicaciones Inyectables mediante respuesta de un cuestionario electrónico, validado entre septiembre y diciembre de 2017. Resultados: Teniendo en cuenta las 1.295 respuestas computadas, se identificaron inconformidades como el uso de frascos de dosis múltiples para dos o más pacientes (10,8%), la reutilización de insumos de un solo uso, como jeringas para la salinización de diferentes pacientes (1,2%) y el reencapuchado de agujas después de su uso (4,9%). Sobresalió la adhesión al uso de guantes para las inyecciones intravenosas (80,5%) y la falta de capacitación sobre la manipulación de dispositivos de seguridad (13%). Los datos correlativos señalaron que, a mayor edad, mejor la conducta referida en la práctica de los inyectables. Conclusión: Aunque la mayoría de las conductas se configuran dentro de las Buenas Prácticas de Medicaciones Inyectables, se informa sobre la existencia de prácticas de riesgo, como el compartir insumos de un solo uso. La capacitación en el uso de dispositivos de seguridad aún no es una realidad para todos los profesionales y muchos han declarado que raramente se los entrena en esa área.

ABSTRACT Objective: To identify the self-reported injectable medications of nursing professionals in the state of São Paulo. Method: Survey study that assessed the self-reported frequency of injection medications through a validated electronic questionnaire, applied from September to December 2017. Results: The 1,295 computed responses showed non-compliances such as sharing multidose vials for two or more patients (10.8%), reusing single-use supplies, such as use of saline flush syringes for different patients (1.2%) and needle recapping after use (4.9%). Greater adherence to glove use for administration of intravenous injections (80.5%) and lack of training for handling safety devices (13%) were reported. Correlational data showed that, the older the age, the better the self-reported injecting practices. Conclusion: Although most practices are within Safe Injecting practices, there are reports of risky practices, such as sharing single-use supplies. Training for the use of safety devices is not yet a reality for all professionals, since many reported it as rare.

The safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with inermediate or higer-risk myelodysplastic syndrome / 中华内科杂志

To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine combined with arsenic trioxide in patients with intermediate or high-risk myelodysplastic syndrome (MDS). Three of the total 11 MDS patients achieved complete remission (CR) and 6 achieved hematological improvement (HI), 1 stable disease (SD), and 1 progressive disease (PD). One patient was treated with allogeneic hematopoietic stem cell transplantation (allo-HSCT). The median follow-up time was 413(90-1 275) d. Nine patients were still alive. Low dose subcutaneous decitabine combined with arsenic trioxide can be an alternative regimen for intermediate or high-risk MDS patients.

Clinical efficacy and safety of low﹣dose decitabine subcutaneous injection combined with arsenicals in treatment of medium﹣and high﹣risk myelodysplastic syndromes / 白血病·淋巴瘤

Objective To explore the clinical efficacy and safety of low﹣dose decitabine subcutaneous injection combined with arsenicals in the treatment of medium﹣ and high﹣risk myelodysplastic syndromes (MDS). Methods Eight cases of medium﹣ and high﹣risk MDS without allogeneic hematopoietic stem cell transplantation in the Affiliated Cancer Hospital of Zhengzhou University and Xinhua Area Hospital of Pingdingshan City from January 2015 to August 2018 were retrospectively analyzed. The patients were given subcutaneous injection of low﹣dose decitabine combined with arsenicals. The specific regimen was as follow:0.1-0.2 mg/kg of decitabine, subcutaneous injection 2 times/week, 4 weeks in total; arsenic injection 10 mg/time or 0.16 mg/kg, intravenous administration, 1 time/d, 4 weeks; compound Huangdai tablets 60 mg/kg per day, 3 times orally. The efficacy and adverse reactions were observed. Results In 8 patients, there were 5 male and 3 female, with an average age of 61.4 years old (44-80 years old) Eleven cases were refractory anemia with excess blasts (RAEB), 6 cases were RAEB﹣2, 1 case was refractory cytopenia with multilineage dysplasia (RCMD) with bone marrow fibrosis (MF). Three of the patients had previously received treatment with decitabine. All patients completed the treatment successfully and no treatment﹣related deaths occurred. By the end of follow﹣up, 2 patients had complete remission, 4 patients had complete bone marrow remission with hematologic improvement, 1 patient had stable disease, and 1 patient had disease progression. For 2 patients who had been treated with decitabine regimen, the regimen of re﹣administered decitabine plus arsenic was still effective. Eight patients had more than level 2 of myelosuppression, except for one patient with intestinal infection due to unclean diet and one patient with mild pulmonary infection. The remaining 6 patients had no associated infection and heart, liver, kidney and other adverse reactions. Conclusion Low﹣dose decitabine subcutaneous injection combined with arsenicals is safe and could be a new treatment for the medium﹣ and high﹣risk MDS.

One case of severe subcutaneous soft tissue infection caused by nonstandard insulin injection / 中华烧伤杂志

On January 1st 2018, a male 44 years old diabetic patient with subcutaneous soft tissue infection in right thigh was admitted to our hospital. The patient repeatedly used the same needle to inject insulin subcutaneously in the unsterilized right thigh, and his blood glucose was badly controlled in the long term. Severe subcutaneous soft tissue infection of the right thigh occurred after his fatigue, accompanied with ketoacidosis. Then he received conservative treatment in the local hospital for one month, but the infection persisted. After being transferred to our hospital, we highly suspected the diagnosis of necrotizing fasciitis according to previous test indicators and local B-ultrasound results, but suggestion of aggressive surgery was refused. So we treated him with conservative therapies using sensitive antibiotics and supportive remedies. The patient was basically healed after treatment of 1 month and he was recovered well during the follow-up 2 months after discharged from our hospital. This case emphasizes the importance of standard injection of insulin and early diagnosis of severe subcutaneous soft tissue infection.

Treatment for patient with chronic postherpetic neuralgia / 中华全科医师杂志

Fifty postherpetic neuralgia (PHN) patients with a course ≥3 years and the Pain Numeric Rating scale (NRS)≥5 were included in the analysis.All patients were treated with nerve block and subcutaneous injection in the affected area.The paravertebral nerve blocks were performed by injecting 5 ml lidocaine in the concentrations of 0.3％;the concentration of lidocaine for branch blockage and peripheral nerves was 1.0％,and that for subcutaneous injection was 0.3％,respectively;2 mg dexamethasone and 0.5 mg vitamin B12 were added in the injections.The NRS scores and quality of life scores were documented before and after the treatment.The NRS score was significantly decreased at different time points of treatment (F=279.6,P＜0.01).At the end of the treatment and at 1 month,3months,6months of follow-up,the scores were significantly lower than those before the treatment.All patients showed enormous improvement in the quality of life at 1,3 and 6 months after treatment.The pain relief was "excellent" or "good" in 38 cases.The efficacy of treatment is associated with skin scar and allodynia.The study indicates that nerve block and subcutaneous injection has a satisfactory efficacy in treatment of chronic postherpetic neuralgia.

Effect of duration of subcutaneous injection on the extent of bruising at injection sites among patients receiving low-molecular weight heparin:a Meta-analysis / 中国实用护理杂志

Objective To evaluate the effect of duration of subcutaneous injection on the extent of bruising at injection sites among patients receiving low- molecular weight heparin. Methods Randomized clinical trials and quasi-experimental within-subject design that assessed the effect of subcutaneous duration on the bruising of injection sites were selected in Cochrane library, JBI evidence-based practice medical and nursing database, PubMed biomedical information retrieval platform, Medline general medical literature retrieval database. RevMan5.3 software was used to analyze the data after quality assessment, and data extraction were made for eligible trials. Results A total of 9 trials were included. The results of Meta-analysis supported the 30 s duration injection technique on reducing the rate of bruising of injection sites than 10 s duration injection technique (odds ratio was 0.34,95%confidence interval 0.25-0.47, P 0.05). Conclusions Increasing the length of low-molecular weight heparin subcutaneous injection can reduce the rate of bruising. While it could not effectively reduce the area.

The clinical safety and efficacy of low dose subcutaneous decitabine in treating acute myeloid leukemia and intermediate-or higer-risk myelodysplastic syndromes in the elderly patients / 中华内科杂志

To retrospectively analyze the safety and efficacy of low dose subcutaneous decitabine regimen in patients with acute myeloid leukemia (AML) and intermediate-or higer-risk myelodysplastic syndrome (MDS).Of 6 AML cases,2 achieved complete remission (CR),2 with partial remission(PR),1 with stable disease(SD),1 with progressive disease(PD).As to the 8 MDS patients,one achieved CR and 6 with hematologic improvement (HI),1 case SD.Low dose subcutaneous decitabine regimen could be an alternative choice of older AML or MDS patients.

The Relationship of a Combination of Human Adipose Tissue-Derived Stem Cells and Frozen Fat with the Survival Rate of Transplanted Fat

BACKGROUND: The survival rate of grafted fat is difficult to predict, and repeated procedures are frequently required. In this study, the effects of the freezing period of harvested adipose tissue and the addition of human adipose tissue-derived stem cells (ASCs) on the process of fat absorption were studied. METHODS: Adipose tissue was obtained from patients who underwent a lipoaspirated fat graft. The fat tissue was cryopreserved at -20degrees C in a domestic refrigerator. A total of 40 nude mice were used. The mice in the experimental group received three different subcutaneous injections in the back: an injection of fresh fat and ASCs, an injection of fat that had been frozen for one month and ASCs, and an injection of fat that had been frozen for two months and ASCs. The control mice received fat grafts without ASCs. The mice were sacrificed at four or eight weeks after the procedure, and the grafted fat tissues were harvested. The extracted fat was evaluated using photographic analysis, volume measurements, and histological examination. RESULTS: In the control group, the fat resorption rates four weeks after transplantation in the grafts of fresh fat, fat that had been frozen for one month, and fat that had been frozen for two months were 21.14%, 22.46%, and 42.56%, respectively. In the experimental group, the corresponding resorption rates were 6.68%, 13.0%, and 33.9%, respectively. CONCLUSIONS: ASCs can increase the fat graft survival rate. The use of ASCs in fat grafting can reduce the need for repeated fat grafts and provide good long term results.

Experimental study on inguinal subcutaneous immunotherapy for allergic rhinitis in mice / 中国免疫学杂志

Objective:To explore the feasibility of inguinal subcutaneous immunotherapy for allergic rhinitis ( AR ) in mice. Methods:36 female BALB/c mice were divided randomly into six groups( n=6 per group) including the control A,the model A, the treatment A groups,and the control B,the model B,the treatment B groups(inguinal subcutaneous immunotherapy for group A, cervical back subcutaneous immunotherapy for for group B). AR model was established with ovalbumin. At 25 to 55 days,ovalbumin im-munotherapy were performed in treatment groups,once two days,15 times totally. After intranasal rechallenge was performed at 56 to 62 days the AR symptom scores were documented. The eosinophils(EOS)in the nasal mucosa were measured by chromotropic acid 2R staining. Ovalbumin-specific IgE( OVA-sIgE) in the serum and expression of interferon-γ and interleukin-4 in the nasal lavage were measured by enzyme-linked immunosorbent assay meanwhile the ratio of interferon-γ and interleukin-4 was calc μlated. SPSS17. 0 software was used to analyze the data. Results:Before treatment ,the AR symptom scores of the model and treatment groups were more than 5. After treatment,the treatment A group were less than 5. The EOS count of the control A,model A,treatment A groups and the control B,model B, treatment B groups was 0. 78 ± 0. 31, 21. 60 ± 2. 90, 10. 43 ± 2. 56, 0. 83 ± 0. 46, 22. 44 ± 3. 39, 23. 40 ± 4. 24, respectively. The EOS count of the treatment A group was significantly lower than those in model A group ( P0. 05 ) . OVA-sIgE expressed was negative in control groups and positive in other groups. The ratio of interferon-γ and interleukin-4 was 10. 75 ± 3. 38,10. 38 ± 3. 08,3. 02 ± 0. 69,2. 71 ± 0. 89,2. 52 ± 0. 30,5. 45±1. 41,respectively. The ratio in treatment A group was significantly higher than those in model A group(P0. 05 ) . Conclusion: Inguinal subcutaneous immunotherapy has a good effect on this disease. It spends short time ,has simple operation and good feasibility,which is a novel treatment method for AR in mice.

Comparison of therapeutic effect of different insulin administration route in treatment of juvenile type 1 diabetes mellitus / 天津医药

Objective To compare the therapeutic efficacy of two different administration routes of insulin administra?tion on juvenile type 1 diabetes mellitus (T1DM) complicated with diabetic ketoacidosis(DKA). Methods A total of 223 cases of juvenile T1DM was included in this study, among which 98 were complicated with DKA. Insulin was delivered through either continuous subcutaneous insulin infusion(CSII) by insulin pump or via multiple subcutaneous insulin injec?tion (MSII). Recovery period of blood glucose, insulin doses that were adminstrated, the urinary ketone bodies clearance time, the recovering time from DKA and the frequency of hypoglycemia incidence were all compared between these two routes. Results Both CSII and MSII routes reversed blood glucose and DKA effectively. However the recovering time of blood glucose and DKA, insulin dosage,the urinary ketone bodies clearance time and the frequency of hypoglycemia inci?dence all improved better or quicker in CSII than in MSII. Conclusion CSII by insulin pump is safer and more effective than MSII in the treatment of junvenile T1DM with metabolic disturbance and diabetic ketoacidosis.

Eficacia de la inmunoterapia subcutánea con extractos de ácaros en adultos asmáticos / Effectiveness of subcutaneous immunotherapy with mite extracts in asthmatic adults

Fundamento: la inmunoterapia alergeno específica constituye el único tratamiento capaz de modificar el curso natural de las enfermedades alérgicas, tiene efecto multiorgánico y duradero a largo plazo después de suspender su administración y se han probado sus efectos preventivos, tanto en la prevención de nuevas sensibilizaciones como en la progresión de la rinitis al asma. Objetivo: evaluar la eficacia de una nueva pauta de inmunoterapia subcutánea con extractos alergénicos de ácaros en adultos asmáticos. Método: se realizó un ensayo clínico fase II, abierto, aleatorizado en 50 pacientes con diagnóstico de asma bronquial leve o moderada, sensibles a ácaros del polvo por prueba de Prick .La población objeto de estudio estuvo constituida por 200 pacientes con antecedentes patológicos de asma bronquial y edades entre 18 y 50 años, que acudieron a la consulta de Alergología del Hospital Universitario Manuel Ascunce Domenech, desde mayo de 2011 a mayo de 2012. A los mismos se les administró inmunoterapia subcutánea con extractos de ácaros (Dermatophagoides pteronyssinus, y Blomia tropicalis) a concentraciones de 20 UB/ml, 200 UB/ ml, 2 000 UB/ml y 20 000 UB/ml en el primer grupo, según el esquema propuesto por el BIOCEN, se alcanzó la dosis de mantenimiento en 13 semanas a intervalos semanales. El segundo grupo recibió pauta convencional de 16 semanas. Resultados: en la evaluación de la eficacia se comprobó una reducción de los síntomas clínicos y del consumo de medicación al final del tratamiento en ambos grupos pero de manera significativa en el grupo estudio (p=0,020). La reactividad cutánea a los ácaros disminuyó significativamente en el grupo estudio con respecto al grupo control. Conclusiones: se demuestró un alto grado de eficacia de esta pauta más acortada con extractos de ácaros, lo que garantiza una adhesión al tratamiento superior a la pauta de 16 semanas con frecuencia bisemanal.

Background: allergen-specific immunotherapy is the only treatment capable of modifying the natural course of allergic diseases; it has multiple organ and long term effect after stopping its administration and its preventive effects have been tested, both in the prevention of new sensitizations and in the progression of rhinitis to asthma. Objective: to evaluate the effectiveness of a new subcutaneous immunotherapy schedule with mite extracts in asthmatic adults. Method: a phase II, open, randomized clinical trial was conducted in 50 patients with diagnosis of mild or moderate bronchial asthma, sensitive to dust mites by Prick test. The study population was constituted by 200 patients with a pathological history of bronchial asthma and aged between 18 and 50 years, who were treated in the Allergology consultation at the University Hospital Manuel Ascunce Domenech, from May 2011 to may 2012. They were given subcutaneous immunotherapy with mite extracts (Dermatophagoides pteronyssinus and Blomia tropicalis) at concentrations of 20 ml/UB 200 UB / UB/ml 2 000 and 20 000 ml/UB/ml in the first group, according to the schedule proposed by BIOCEN, it was reached the maintenance dose in 13 weeks at weekly intervals. The second group received conventional schedule of 16 weeks. Results: it was found a reduction of clinical symptoms as well as in medication consumption at the end of the treatment in both groups, but significantly in the study group (p=0,020). Skin reactivity to mites significantly decreased in the study group regarding the control group. Conclusions: a high degree of effectiveness of this new schedule with mites’ extracts was demonstrated, this guarantees a greater adhesion to treatment, which it is far superior to the previous 16-week schedule with a twice-weekly frequency.

Análise da lipoenxertia estruturada na redefinição do contorno facial / Analysis of structured fat grafting for redefining facial contours

INTRODUÇÃO: A enxertia de gordura como preenchimento no rejuvenescimento e melhoria do contorno facial vem sendo usada por alguns autores e demonstra um potencial excelente como método de escolha para essa finalidade, uma vez que tem como premissa o princípio básico de corrigir as deformidades com o tecido mais semelhante possível. O objetivo deste trabalho foi avaliar clinicamente a eficiência da enxertia de gordura estruturada na redefinição do contorno facial. MÉTODO: Foi realizada análise retrospectiva de 39 pacientes submetidos a lipoenxertia estruturada para a redefinição do contorno facial, entre 2002 e 2012. A seleção de pacientes incluiu correção de deformidades, assimetrias, harmonização do contorno e aumento da projeção óssea, mas excluiu o rejuvenescimento per se. A avaliação do resultado clínico foi realizada pelo paciente e pelo cirurgião, com auxílio de documentação fotográfica pré e pós-operatória. O resultado clínico foi classificado pelo paciente e cirurgião, empregando escala que variava de 1 a 3: (1) o objetivo não foi alcançado de forma alguma; (2) o objetivo foi alcançado parcialmente; ou (3) o objetivo foi alcançado totalmente. Foi realizado, também, levantamento de prontuários para obtenção dos seguintes dados: idade, alteração ponderal, volume enxertado por área, número de sessões de enxertia realizadas, história de tabagismo e complicações. RESULTADOS: As médias das avaliações do cirurgião e paciente foram, respectivamente, 2,6 ± 0,6 e 2,7 ± 0,5, havendo correlação estatisticamente significante (P < 0,0001). Não foi encontrada relação significativa entre as avaliações e idade, alteração ponderal, volume de enxertia ou tabagismo, com uma única exceção. CONCLUSÕES: A lipoenxertia estruturada demonstrou ser eficiente adjuvante na redefinição do contorno facial e sua eficiência não foi prejudicada por idade, alteração ponderal ou tabagismo. O volume a ser enxertado deve ser adequado às necessidades específicas de cada área.

INTRODUCTION: Fat grafting as a filling method for the rejuvenation and enhancement of facial contours was demonstrated by some authors to be an excellent alternative method for redefining facial contours, based on the premise that the donor tissue used in the correction of the deformities has similar characteristics as the recipient tissue. The objective of the present study was to clinically evaluate the efficiency of structured fat grafting when redefining facial contours. METHODS: A retrospective evaluation was performed in 39 patients who underwent structured fat grafting to redefine their facial contours between 2002 and 2012. The patients selected included those who underwent corrections of deformities, asymmetrical features, contour smoothing, and increased bone projection. Patients who underwent facial contour rejuvenation were excluded. The clinical outcome assessment was performed by the patient and surgeon, with the aid of preoperative and postoperative photographic documentation. The clinical outcome was rated by the patient and surgeon, using a scale ranging from 1 to 3, defined as follows: 1, the objective has not been achieved in any way; 2, the objective was partially achieved; or 3, the objective was fully achieved. In addition, a survey was conducted using the patients' medical charts to obtain the following data: age, weight change, volume grafted by area, number of grafting sessions performed, history of smoking, and complications. RESULTS: The mean surgeon and patient assessment scores were 2.6 ± 0.6 and 2.7 ± 0.5, respectively, with a statistically significant correlation (P < 0.0001). No significant relationship was found between the assessments and age, weight change, graft volume, or smoking habit, with the exception of the cheekbone area. CONCLUSIONS: Structured fat grafting proved to be an efficient adjuvant technique for redefining facial contours, and its efficiency was not affected by age, weight change, or smoking habit. However, the fat volume to be grafted should be adequate for the specific needs of each area.

A comparative study of the effects of needle free (INJEX30) versus insulin pen injection on insulin absorption in diabetic patients / 中华内科杂志

Objective To evaluate the effect of the needle free injection system (INJEX30) and insulin pen on insulin absorption and glycemic control in diabetic patients.Methods A total of 30 diabetic patients on insulin therapy without obvious complications were enrolled in the study with average BMI of 25.24 kg/m2.A comparison study was carried out in those subjects with the INJEX30 and insulin pen at 1 st day and 5th day.After an overnight fasting of 8-10 h,a standard mixed meal(50 g bread,50 g egg and 250 ml milk) was given to each patient.Blood samples at 0,20,40,60 min of the standard mixed meal were collected to test plasma glucose,serum insulin and C peptide.Results No difference was shown in fasting plasma glucose,serum insulin and C peptide between the patients with the two injection methods.The area under the curve (AUC) of plasma glucose and serum C peptide was significantly lower after the INJEX30 injection than that after insulin pen injection [plasma glucose AUC (542 ± 172) min · mmol · L-1 vs (601 ±199) min· mmol · L-1,P ＜0.01; C peptide AUC (70 ±53) min · μg · L-1 vs (80 ±58) min · μg · L-1,P ＜0.01].The AUC of serum insulin was significantly higher after the INJEX30 injection than that after insulin pen injection [serum insulin AUC(5621 ± 3790) min · mIU · L-1 vs(4285 ± 3376) min · mIU · L-1,P ＜0.01].No difference was found in the AUC of serum insulin between the two injection methods in the patients with BMI below 25.24 kg/m2,while the AUC of serum insulin was significantly higher after the INJEX30 injection than the insulin pen injection in the patients with BMI above 25.24 kg/m2 [serum insulin AUC(6453 ± 4099) min · mIU · L-1 vs (4879 ± 3701) min · mIU · L-1,P ＜0.01].Conclusion The INJEX30 improves the serum insulin level which may lead to a beneficial effect on the glycemic control.Such effect is more obvious in the overweight patients.

The efficacy comparison of insulin aspart 30 and insulin glargine intensive treatment in the treatment of type 2 diabetes / 中国基层医药

Objective To compare efficacy of different insulin intensive treatment in the treatment of type 2 diabetes,to provide a reference for the programming of intensive treatment of diabetes.Methods 60 type 2 diabetes patients met inclusion criteria were divided into insulin aspart 30 intensive treatment group (I group) and insulin glargine intensive treatment group(Ⅱ group) by random number table,30 cases of each group,I group was given subcutaneous injection of insulin aspart 30,tid,Ⅱ group was given subcutaneous injection of insulin glargine at bedtime,qd.Both groups were treated for 14d,record the time of blood glucose control,observed the occurrence of low blood sugar,detected the HOMA-IR,HOMA-β and clinical efficacy.Results After treatment,the fasting glucose,2h postprandial blood glucose,glycosylated hemoglobin,HOMA-IR,HOMA-β of Ⅰ group and Ⅱ group were (6.0 ± 0.9)mmol/L vs (5.4 ±1.1)mmol/L,(7.4 ± 1.9)mmol/L vs (6.6±2.3)mmol/L,(6.2 ± 1.7)％ vs (6.0 ± 1.9)％,(1.11 ±0.32) vs (1.01 ±0.35),(5.23 ± 1.63) vs (5.46 ±1.41),the fasting glucose,2h postprandial blood glucose,glycosylated hemoglobin,HOMA-IR of Ⅰ and Ⅱ group after treatment compared with those before treatment,the differences were statistically significant.The HOMA-β of Ⅰ and Ⅱ group was significantly higher than that before treatment,the difference was statistically significant.The fasting blood glucose,2h postprandial blood glucose,glycosylated hemoglobin,HOMA-IR,HOMA-β before and after treatment between two groups was not significantly different,the time of blood glucose control between Ⅰ and Ⅱ group were (6.5 ± 2.8) d vs (6.2 ± 2.5) d,the difference was not statistically significant,the low blood sugar of Ⅰ and group Ⅱ was 20％ (6/30) vs 3％ (1/30),there was statistically significant difference.Conclusion The insulin aspart 30 and insulin glargine intensive treatment all can control blood sugar,increase insulin β-cell function,reduce insulin resistance in the treatment of type 2 diabetes,but insulin glargine significantly reduced the incidence of hypoglycemia and insulin glargine is the ideal insulin for blood glucose security control.

Research of immunogenicity of mycobacteriophage D29 toward tuberculosis therapy / 中华传染病杂志

Objective To investigate the immunogenicity of mycobacteriophage D29 (phage D 29) in guinea pig models with different delivery routes,and provide information for the application of phages in tuberculosis (TB) therapy.Methods Hartley guinea pigs were administrated with phage D29 through inhalation,intranasal drop or subcutaneous injection for 6 times within 35 days.7H9 broth aerosol inhalation and 0.85 ％ NaCl solution aerosol inhalation were set as solvent and negative controls,respectively.Anti-phage D29 neutralizing antibodies in sera collected weekly were measured by phage reduction neutralizing test (PRNT) and cytokine levels (interleukin-2,interleukin-4 and interferon-γ) were detected at day 35 by enzyme linked immunosorbent assay (ELISA).The data were analyzed by ANOVA and nonparametric test.ResultsNeutralizing antibodies were both negative in two control groups,while low-titer neutralizing antibodies (below 1 ∶ 100) appeared in inhalation and intranasal drop groups only at day 7 and day 14. Nevertheless, neutralizing antibodies were continuously detected in subcutaneous injection group,which increased rapidly and reached 1∶ 16 365.6 at day 35. After 35 days of experiments,serum concentrations of interleukin-2 (x2 =2.7605,P＞0.05),interleukin-4 (F=2.17,P＞0.05) and interferon-γ(F=0.75,P＞0.05) among three treatment groups and two control groups were all not significantly different.ConclusionsThe titer of anti-phage 29 neutralizing antibodies induced by inhalation or intranasal drop administration of phage D29 are both significantly lower than subcutaneous injection.Phage D29 administration doesn’t change the levels of cytokines,which indicates that it may not break the helper T cell (Th)1/Th2 balance.

Administração de antibióticos por via subcutânea: uma revisão integrativa da literatura / Administration of antibiotics subcutaneously: an integrative literature review

OBJETIVO: Caracterizar os artigos científicos relacionados ao uso de antibióticos por via subcutânea em pacientes com difícil acesso venoso em cuidados paliativos quanto à tolerância local e eficácia terapêutica. MÉTODOS: Revisão integrativa da literatura realizada nas bases de dados LILACS, CINAHL, PUBMED, EMBASE e Biblioteca Cochrane, utilizando-se como referencial teórico a Prática Baseada em Evidências. RESULTADOS: 17 artigos foram selecionados com dez antibióticos diferentes, sendo o Ceftriaxona, o antibiótico mais estudado. Constatou-se a eficácia terapêutica com base nos parâmetros farmacocinéticos e clínicos. A tolerância local esteve associada à maior diluição dos antibióticos. Com administração de aminoglicosídeos, observaram-se lesões graves e necrose tecidual. A baixa tolerância reforça a restrição de uso apenas para essa classe de antibióticos. CONCLUSÃO: As previsões de eficácia terapêutica e a boa tolerância sugerem uma possibilidade a ser considerada quando se deseja uma via de administração parenteral alternativa, porém recomenda-se cautela, visto que nenhum dos estudos avaliou pacientes em cuidados paliativos.

OBJECTIVE: To characterize scientific articles related to the use of antibiotics by the subcutaneous route in patients with difficult venous access in palliative care, regarding local tolerance and therapeutic efficacy. METHODS: Integrative literature review conducted in the databases of LILACS, CINAHL, PubMED, EMBASE and the Cochrane Library, using Evidence-Based Practice as a theoretical framework. RESULTS: Seventeen articles were selected with ten different antibiotics, with ceftriaxone being the most studied antibiotic. Therapeutic efficacy was observed based on pharmacokinetic and clinical parameters. The local tolerance was associated with greater dilution of antibiotics. With administration of aminoglycosides, serious injuries and tissue necrosis were observed. A low tolerance reinforced the restriction of use only to this class of antibiotics. CONCLUSION: The predictions of therapeutic efficacy and good tolerance suggest a possibility to be considered when there is need of an alternative parenteral route of administration, but caution is advised, since none of the studies evaluated patients in palliative care.

OBJETIVO: Caracterizar los artículos científicos relacionados al uso de antibióticos por vía subcutánea en pacientes con difícil acceso venoso en cuidados paliativos en cuanto a la tolerancia local y eficacia terapéutica. MÉTODOS: Revisión integrativa de la literatura realizada en las bases de datos LILACS, CINAHL, PUBMED, EMBASE y Biblioteca Cochrane, utilizándose como referencial teórico la Práctica Basada en Evidencias. RESULTADOS: Fueron seleccionados 17 artículos con diez antibióticos diferentes, siendo la Ceftriaxona, el antibiótico más estudiado. Se constato la eficacia terapéutica con base en los parámetros farmacocinéticos y clínicos. La tolerancia local estuvo asociada a la mayor dilución de los antibióticos. Con administración de aminoglicosídeos, se observaron lesiones graves y necrosis tecidual. La baja tolerancia refuerza la restricción de uso apenas para esa clase de antibióticos. CONCLUSIÓN: Las previsiones de eficacia terapéutica y la buena tolerancia sugieren una posibilidad a ser considerada cuando se desea una vía de administración parenteral alternativa, sin embargo se recomienda cautela, puesto que ninguno de los estudios evaluó a pacientes en cuidados paliativos.

Randomized clinical trial to assess pain and bruising in medicines administered by means of subcutaneous and intramuscular needle injection: Is it necessary to have needles changed? / Ensaio clínico randomizado para avaliação de dor e hematoma em administração de medicamentos por via subcutânea e intramuscular: há necessidade de troca de agulhas? / Ensayo clínico aleatorio para evaluación del dolor y hematoma durante la administración de medicamentos por vía subcutánea e intramuscular: ¿Es necesario cambiar las agujas?

This clinical trial aimed at comparing the intensity of pain and bruising by subcutaneous and intramuscular injections using and retractable fixed syringes and needles and syringes with no needles combined, at a public hospital in Sao Paulo, for six months. We evaluated the perception of pain in case of intramuscular (n=1000) and subcutaneous injections (n=240). In subcutaneous application, bruise formation was also verified. Pain and bruising scores were higher in the group with no needles combined (p<0.001) and (p<0.029), respectively. The test power in relation to the pain scale of was 0.98. The use of retractable fixed needles is recommended in the application of subcutaneous and intramuscular injections. Clinical trial registration number: NCT01271608.

Este ensaio clínico teve como objetivo comparar a intensidade da dor e hematoma consequentes a injeções por via subcutânea e intramuscular, utilizando seringas e agulhas fixas retráteis e seringas com agulhas não conjugadas, em hospital público na cidade de São Paulo, durante seis meses. Foi avaliada a percepção da dor na injeção intramuscular (n=1.000) e na subcutânea (n=240). Na aplicação por via subcutânea, verificou-se também a formação de hematoma. A pontuação de dor e hematoma foi maior no grupo com agulhas não conjugadas (p<0,001 e p<0,029, respectivamente). O poder do teste em relação à escala de dor foi de 0,98. Recomenda-se o uso de agulha fixa retrátil na aplicação de injeções intramusculares e subcutâneas. Registro de ensaio clínico nº NCT01271608.

Este ensayo clínico tuvo como objetivo comparar la intensidad del dolor y hematoma de inyecciones por vía subcutánea e intramuscular utilizando jeringas y agujas fijas retráctiles y jeringas con agujas no conjugadas, en un hospital público en la ciudad de Sao Paulo, durante seis meses. Fue evaluada la percepción del dolor de la inyección intramuscular (n=1000) y la subcutánea (n=240). En la aplicación por vía subcutánea se verificó también la formación de hematoma. La puntuación del dolor y hematoma fue mayor en el Grupo con agujas no conjugadas (p<0,001) y (p<0,029), respectivamente. El poder de la prueba en relación a la escala de dolor fue de 0,98. Se recomienda el uso de aguja fija retráctil en la aplicación de inyecciones intramusculares y subcutáneas. Registro de ensayo clínico nº NCT01271608.